- Open Access
Mechanisms of action of Fu Fang Gang Liu liquid in treating condyloma acuminatum by network pharmacology and experimental validation
BMC Complementary Medicine and Therapies volume 23, Article number: 128 (2023)
Condyloma acuminatum (CA) is a sexually transmitted disease characterized by the anomalous proliferation of keratinocytes caused by human papillomavirus (HPV) infection. Fu Fang Gang Liu liquid (FFGL) is an effective externally administered prescription used to treat CA; however, its molecular mechanism remains unclear. This study aimed to identify and experimentally validate the major active ingredients and prospective targets of FFGL.
Network pharmacology, transcriptomics, and enrichment analysis were used to identify the active ingredients and prospective targets of FFGL, which were confirmed through subsequent experimental validation using mass spectrometry, molecular docking, western blotting, and in vitro assays.
The network pharmacology analysis revealed that FFGL contains a total of 78 active compounds, which led to the screening of 610 compound-related targets. Among them, 59 overlapped with CA targets and were considered to be targets with potential therapeutic effects. The protein–protein interaction network analysis revealed that protein kinase B (Akt) serine/threonine kinase 1 was a potential therapeutic target. To further confirm this result, we performed ribonucleic acid sequencing (RNA-seq) assays on HPV 18+ cells after FFGL exposure and conducted enrichment analyses on the differentially expressed genes that were screened. The enrichment analysis results indicated that the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway may be a key pathway through which FFGL exerts its effects. Further in vitro experiments revealed that FFGL significantly inhibited the activity of HPV 18+ cells and reduced PI3K and Akt protein levels. A rescue experiment indicated that the reduction in cell viability induced by FFGL was partially restored after the administration of activators of the PI3K/Akt pathway. We further screened two active components of FFCL that may be efficacious in the treatment of CA: periplogenin and periplocymarin. The molecular docking experiments showed that these two compounds exhibited good binding activity to Akt1.
FFGL reduced HPV 18+ cell viability by inhibiting key proteins in the PI3K/Akt pathway; this pathway may represent an essential mechanism through which FFGL treats CA. Periplogenin and periplocymarin may play a significant role in this process.
Condyloma acuminatum (CA) is a sexually transmitted disease with high transmission and recurrence rates that is caused by human papillomavirus (HPV), which belongs to the alpha genus of the papilloma vacuolar virus . Low-risk HPV is the most prevalent type of HPV that causes CA; however, infection with high-risk HPV alone or in combination is also common in CA cases . Patients with high-risk HPV infection also have a higher risk of developing persistent infection and experiencing a longer disease duration than those without high-risk HPV infection . Moreover, high-risk HPV is a key factor associated with certain types of cancer, such as cervical cancer, penile cancer, and head and neck cancers .
The most prominent clinical feature of CA is the production of warts caused by the abnormal proliferation of epithelial cells. HPV enters basal cells through tiny wounds and replicates in large quantities in keratinocytes as basal cells differentiate, promoting the abnormal proliferation of epithelial cells and producing warts [5,6,7,8,9]. The classical theory suggests that this process is closely related to the expression of oncoproteins E6 and E7. These oncoproteins interfere with p53 and phosphorylated retinoblastoma tumor suppressor protein (pRb), affecting the regulation of the host cell cycle and apoptosis [10,11,12]. Furthermore, other signaling pathways are instrumental in the abnormal cellular proliferation caused by HPV infection. A number of studies have reported that the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway is activated in HPV-related diseases and certain cancers [13,14,15], which can lead to accelerated cell division, metabolic reprogramming, and the inhibition of autophagy . HPV E6 can promote cell division by upregulating the expression of genes in the P13K/Akt pathway and increasing the phosphorylation level of PI3K . HPV E7 markedly increases the activity of Akt in keratinocytes by inactivating the pRb family of proteins . E7 can also activate Akt by promoting Akt phosphorylation at Thr308 and Ser473 residues . One study showed that after intervention with P13K inhibitors, Akt phosphorylation in keratinocytes transfected with HPV 16 was significantly reduced .
Traditional Chinese medicine (TCM) has a long history of treating CA. Fu Fang Gang Liu liquid (FFGL) is an effective externally administered prescription for CA that was first described by a well-known Chinese dermatologist, Xu Xian. FFGL comprises the following four herbs: Da Qing Ye (Isatis indigotica Fort.), E Zhu (Curcuma phaeocaulis Val.), Gang Liu (Periploca sepium Bge.), and Bu Gu Zhi (Psoralea corylifolia L.). The creation of FFGL was originally based on folk remedies used for the treatment of warts, and it has been used clinically for decades with excellent therapeutic results. Previously, we conducted a clinical study on the topical application of FFGL for CA treatment. The results showed a high wart clearance rate with FFGL treatment, with a lower recurrence rate after treatment than was observed in the podophyllotoxin-treated group . However, the mechanism through which FFGL treats CA requires further elucidation.
TCM compounds have multi-component, multi-target, and multi-pathway characteristics. Network pharmacology is a discipline in which potential targets and mechanisms of drugs are identified by studying the complicated connections between drugs, targets, and disease processes; thus, it can help reveal the mechanisms through which TCM compounds can treat diseases [22,23,24]. This study’s first aim was to characterize the active ingredients and potential targets of FFGL using network pharmacology to reveal its therapeutic mechanisms. The second aim was to validate the prediction targets using mass spectrometry, molecular docking, RNA sequencing (RNA-Seq), and in vitro experiments.
Network pharmacological analysis
Screening of active compounds and determination of action targets
The compounds comprising FFGL were extracted from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP)  and the Encyclopedia of TCM (ETCM) . Pharmacokinetic screening was performed according to the drug absorption, distribution, metabolism, and excretion processes [27, 28]. Considering the therapeutic characteristics of substances for external use, the active ingredients in FFGL with a drug-likeness (DL) ≥ 0.18 were screened out. Most active ingredient targets were identified through the TCMSP, and active ingredients that did not predict target information were supplemented by the PharmMapper  and SwissTargetPrediction  platforms. A standard normalized fit score > 0.9 was set in PharmMapper, and a probability > 0 was set in SwissTargetPrediction to select potential targets. The predicted target protein information was standardized using the UniProt database  to unify genetic names. An Herb-Compound-Target (H-C-T) network was constructed using Cytoscape 3.7.2  to study the relationships between complex components and targets of FFGL.
Target collection and potential CA target prediction
Using “condyloma acuminatum” and “genital warts” as search terms, potential targets of CA were mined from the GeneCards database  and the DisGeNet database , and high-resolution targets larger than the median score were selected. Subsequently, we unified the genetic names using the UniProt database. The intersection of FFGL active component targets and disease targets was then determined. We created an “H-C-T-Disease” (H-C-T-D) network using Cytoscape 3.7.2 to elucidate the connections between FFGL active components and the disease and drug intersection targets.
Protein–Protein Interaction (PPI) network construction and analysis
The cross-targets were committed to the Search Tool for the Retrieval of Interacting Genes/Proteins version 11 (STRING11.0) database . The biological species was set to “Homo sapiens,” and the minimum interaction threshold was pegged at > 0.9 (the confidence level). The targets without protein interaction relationships were hidden, and the PPI network diagram was subsequently obtained. Through Cytoscape3.7.2, the PPI network was visualized, and the appropriate degree value was selected to screen the core targets. According to the methods reported in the literature , we leveraged the Molecular Complex Detection (MCODE) plugin to extract the clustered networks with highly connected attributes.
HeLa cells were obtained from the National Experimental Cell Resource Sharing Platform (Beijing, China). All the TCM tablets used in the FFGL preparation were purchased from Kangmei Pharmaceutical Co., Ltd. (Guangdong, China), including Isatis indigotica Fort., Curcuma phaeocaulis Val., Periploca sepium Bge., and Psoralea corylifolia L.
Preparation of FFGL
Isatis indigotica Fort., Curcuma phaeocaulis Val., Periploca sepium Bge., and Psoralea corylifolia L. herbs were soaked in 1 L of double-steamed water for 30 min according to the clinical dosage and boiled for 1 h. We poured out the liquid medicine and boiled it again with 1 L of double-distilled water for 1 h. The two decoctions were mixed, concentrated into 500 mL of liquid, centrifuged in a molecular sieve at 3,000 kDa to remove macromolecular polysaccharides and polypeptides, and centrifuged at 5,000 × g for 30 min. The centrifuged liquid was concentrated again and lyophilized using a lyophilizer, after which the lyophilized powder was sealed and stored at –80 °C. We dissolved 0.512 g of FFGL extract in 10 mL of sterile double-distilled water into a mother liquor (pH 7.2–7.4), filtered it through a 0.22-micron filter, aliquoted and stored it in a refrigerator at –20 °C, and diluted it to the corresponding concentration in the corresponding medium before use. Next, we characterized the composition of the FFGL lyophilized powder by liquid chromatography–mass spectrometry (LC–MS) at Beijing University of Chinese Medicine. The components identified via LC–MS can be found in Supplementary Table 1.
Cell viability assays
We applied the cell counting kit-8 (CCK-8) method to evaluate the effect of FFGL on cell viability according to the manufacturer’s instructions. HeLa (HPV 18+) cells were seeded into 96-well plates at a cell density of 3 × 104 cells/mL. To detect the temporal and dose-dependent effects of FFGL on cells, we treated the HeLa cells with different FFGL concentrations (0, 20, 40, 80, 160, 320, 640, 1280, 2560, and 5120 µg/mL) for 24 h, 48 h, and 72 h. Next, we added 10 µL of CCK-8 working solution to the cells, gently shaking the plate for 30 s. The reaction was performed for 3 h at 37 °C in an incubator. Finally, the optical density value was measured using an enzyme marker (TECAN, Männedorf, Switzerland) at an excitation wavelength of 450 nm. Similarly, we treated HeLa cells with the PI3K activator 740 Y-P (GlpBio, Montclair, CA, USA) (0, 12.5, 25, 50, 100, 200 µg/mL) in combination with FFGL (80 µg/mL) for 48 h.
We seeded HeLa cells in 6-well plates at a cell density of 9 × 104 cells/mL the night before treatment. The next day, we treated the cells with 160 μg/mL of FFGL for 48 h. The treated cells were collected, and the total RNA was extracted based on the manufacturer’s instructions. The RNA concentration and purity were evaluated using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). Quality-checked mRNAs (RIN ≥ 7 and 28S/18S ≥ 0.7) were added to Oligo (dT) magnetic beads for mRNA isolation, mRNA fragmentation, and cDNA synthesis. The synthesized cDNA fragments were subjected to end-repair, and a single ‘A’ nucleotide was added to the 3’ ends of the blunt fragments. After adaptor ligation, the products were amplified by PCR to generate libraries. The PCR products were denatured to single-stranded loops and then sequenced on a BGISEQ-500 platform (Beijing Genomics Institute, Beijing, China). The raw sequencing data were filtered using SOAPnuke (v1.5.6) software to obtain clean data. Subsequently, the clean data were aligned to the University of California, Santa Cruz (UCSC) human reference genome (hg38) using Bowtie2 (v188.8.131.52) software. Gene expression quantification was performed using RSEM (v1.3.1) software. The statistics describing the RNA quality after filtering can be found in Supplementary Table 2. Detailed RNA-seq data can be found in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) (GSE223380). A |Log2Fold Change|> 1.5 and a q-value < 0.05 were used as the screening criteria to identify differentially expressed genes (DEGs). Volcano maps of the DEGs were generated using HiPlot as previously described . R software (v 4.1.2) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology-Based Annotation System (KOBAS) 3.0  were used to conduct the bioinformatics analysis of the DEGs.
The clusterProfiler packge (v 4.0.3)  in R software was used to conduct the Gene Ontology (GO) enrichment analysis, and the enrichment terms were visualized using tree network diagrams. KEGG [40,41,42] enrichment analysis of DEGs was performed using KOBAS 3.0 and visualized using HiPlot. The Benjamini–Hochberg procedure was used to correct the p-values. Corrected p-values < 0.05 was considered a significant enrichment.
Western blot analysis
We seeded HeLa cells in 6-well plates at a cell density of 3 × 105 cells/mL, then we treated the cells with 160 μg/mL of FFGL at different time points. Subsequently, the HeLa cells were lysed in radioimmunoprecipitation assay buffer for 30 min on ice. After extracting the total protein content, we quantified it using a bicinchoninic acid (BCA) Protein Concentration Assay Kit (Solarbio, Beijing, China) and separated the proteins via 10% or 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis. The separated proteins were then transferred to a polyvinylidene fluoride membrane. Next, they were blocked with 5% skim milk for 45 min and incubated overnight with the following primary antibodies: anti-PI3K (1:1000, CST, Danvers, MA, USA) and anti-Akt (1:1000, CST, USA). Subsequently, the membrane was washed thrice with tris-buffered saline (TBS) containing 0.1% Tween-20 and incubated with a secondary antibody (1:5000, CST, USA) for 1 h. The membrane was exposed to an enhanced chemiluminescence reagent (Millipore, Billerica, MA, USA) and then imaged using an infrared laser scanning instrument (Analytik Jena, Jena, Germany). Protein bands were scanned and analyzed using ImageJ software for optical densitometry for the semi-quantitative determination of the protein expression levels. The experiment was repeated three times.
Molecular docking techniques were used to analyze the interactions between the key components in FFGL and the key targets of CA. The two-dimensional structures of the key components were obtained from structure data files (SDFs) by importing them into the PubChem database ; the SDF structures of these compounds were imported into the Schrödinger molecular docking software and preprocessed using the LigPre module for later molecular docking preparation. The three-dimensional structures of the key targets were downloaded from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) database , and those with ligands of human origin were selected, downloaded, and imported into the Schrödinger molecular docking software. The proteins were preprocessed using the Protein Preparation module, which included the deletion of water molecules, hydrogenation, residue complementation, and charge assignment. The active pockets for molecular docking were defined by the ligands that came with the crystals, and the docking boxes were generated by directly selecting the ligands in the crystals. Screening for standard precision patterns was conducted for the docking of key components of the compounded solution into the defined active pockets, and the docking results were visualized using PyMol V 2.1.0.
Values are expressed as the mean ± standard error of the mean, unless otherwise noted. The statistical significance of differences between the control and treatment groups was assessed using unpaired, two-tailed Student’s t-tests (GraphPad Prism). All comparisons were made relative to untreated controls, and P < 0.05 was considered statistically significant. Unless otherwise stated, three independent experiments were conducted for each variable.
Construction of the H-C-T network
Seventy-eight active ingredients were identified in FFGL, including 18 from Isatis indigotica Fort., seven from Psoralea corylifolia L., 47 from Periploca sepium Bge., and eight from Curcuma phaeocaulis Val. Two of the components, poriferast-5-en-3beta-ol and beta-sitosterol, were common to Isatis indigotica Fort. and Periploca sepium Bge. A total of 610 targets associated with 78 active compounds in FFGL were obtained after removing duplicates, including 163 for Isatis indigotica Fort., 114 for Curcuma phaeocaulis Val., 105 for Psoralea corylifolia L., and 539 for Periploca sepium Bge. The “H-C-T” network of FFGL was constructed and analyzed using Cytoscape to investigate further interactions between components and targets in FFGL (Fig. 1). The “H-C-T” network consisted of 692 nodes and 1,915 edges. Perlatolic acid, periplocymarin, and neridienone A had the greatest number of targets in the H-C-T network, with 100 targets for each component. Among the remaining compounds, periplogenin, beta-sitosterol, hederagenol, and bisdemethoxycurcumin had the next highest numbers of targets, with 90, 75, 72, and 48, respectively. Further details can be found in Supplementary Table 3.
Acquisition of potential targets for CA treatment
The GeneCards and the DisGeNet databases were used to obtain potential targets for CA. After removing duplicate targets contained in both databases, we obtained 346 CA-related targets (Supplementary Table 4). To explore the key CA targets of the active components of FFGL, we overlapped the targets regulated by the active components in FFGL with the CA-related targets, yielding 59 core targets (Supplementary Table 5).
Construction of the H-C-T-D network
The H-C-T-D network was constructed using Cytoscape. The network comprised 132 nodes and 340 edges (Fig. 2). The following top 10 compounds were filtered according to the degree value: ursolic acid, beta-sitosterol, periplogenin, hederagenol, periplocymarin, amyrin, indirubin, corylifolinin, 3’-methoxysecoisolariciresinol, and perlatolic acid (Table 1). Detailed information is provided in Supplementary Table 6.
PPI network construction and clustering analysis of core targets
The 59 potential core targets of FFGL for CA that we acquired were imported into the STRING database to construct a PPI network. Next, we imported the constructed PPI network into Cytoscape for further visualization and in-depth analysis. This network included 59 nodes and 804 edges (Fig. 3A). Each node represents a protein, and the degree value indicates the number of lines connected to one node and is used as a measure of the importance of each node. The size of the nodes and color hue are proportional to the degree value. The edges of the diagram represent the relationship between each node, and the number of lines is proportional to the degree of association between two nodes.
In the PPI network, the average degree value of each node was 27.25, with 31 nodes having a greater-than-average degree value, including AKT1, TP53, SRC, TNF, EGFR, ALB, IL6, VEGFA, STAT3, CCND1, ERBB2, JUN, PTGS2, ESR1, IL1B, PIK3CA PPARG, NFKBIA, IL2, EP300, RELA, CD274, IFNG, TGFB1, CSF2, PTPN11, ICAM1, PGR, CDKN1A, IGF1R, and MAP2K1. These 31 targets revealed the preliminary relationship between potential protein targets of FFGL for the treatment of CA.
The MCODE plugin in Cytoscape was used to discover the crucial clustering of functional modules in the PPI network, and a K-core of 4 was set as the threshold to obtain the clustering of one functional module (Fig. 3B). This clustering network consisted of 35 nodes and 463 edges, with a score of 27.235. The top 10 nodes according to the degree size were AKT1, TP53, SRC, TNF, EGFR, VEGFA, IL6, STAT3, CCND1, and JUN. The core node was Akt1, a member of the serine/threonine protein kinase subfamily that is highly expressed in many tumors and HPV-related diseases [45, 46]. In this clustering module, other nodal proteins are directly or indirectly involved in Akt1 activation, such as the extracellular-associated factors, VEGFA and EGFR, which bind to dimerize the protein . Akt1 modulates events related to cell death and senescence by enhancing the ubiquitinated degradation of p53 promoted by MDM2 . These findings indicate that Akt1, the core node, is involved in the regulation of biological processes such as cell proliferation, differentiation, and migration by connecting with other cytokines in the whole cluster. This analysis of the clustering network suggests that AKT1 is an essential target of FFCL for the treatment of CA. Detailed information is provided in Supplementary Tables 7 and 8.
FFGL can significantly reduce the viability of HPV 18+ cells
To further clarify the effect of FFGL on HPV 18+ cells, HeLa cells containing the entire HPV 18 genome were used. The effect of FFGL on the viability of HeLa cells was examined after 24-, 48- and 72-h interventions. We found that FFGL significantly inhibited the viability of HeLa cells, and the effect was both time- and dose-dependent (Fig. 4).
To further explore the mechanism of action, we collected and sequenced RNA from HeLa cells from the control group and those treated with 160 μg/mL FFGL for 48 h. Based on the screening criteria, we screened 883 DEGs, 354 of which were upregulated and 529 of which were downregulated. Volcano plots of all gene expression data were created (Fig. 5A).
GO and KEGG enrichment analyses
To explore the mechanism through which FFGL inhibits the proliferation of HPV+ cells in more depth, we performed GO enrichment analysis of DEGs using the clusterProfiler package and KEGG enrichment analysis of DEGs using KOBAS 3.0, then visualized the results using HiPlot. The GO enrichment analysis consisted of the following three components: biological process (BP), molecular function (MF), and cellular component (CC). The BP enrichment analysis showed that DEGs were mainly enriched in processes related to the response to extracellular stimuli, steroid biosynthesis, and ERK1 and ERK2 signaling cascades. The MF enrichment analysis showed that DEGs were mainly enriched in processes related to receptor–ligand activity, signaling receptor activator activity, and integrin binding. The CC enrichment analysis showed that the DEGs were mainly involved in collagen-containing extracellular matrices, integrin complexes, and protein complexes involved in cell adhesion (Fig. 5B). Detailed information on enriched pathways is shown in Supplementary Table 9.
The KEGG enrichment analysis revealed that the DEGs were mainly enriched in processes related to cytokine-cytokine receptor interactions, metabolic pathways, PI3K-Akt signaling pathways, and cancer pathways. Figure 5C presents the top 20 of these enriched pathways.
FFGL suppresses the PI3K/Akt pathway
Based on the network pharmacology and transcriptome data, we suggest that FFGL may inhibit the proliferation of HPV 18+ cells by suppressing the PI3K/Akt signaling pathway. We calculated the expression of PI3K- and Akt-related genes in the transcriptome data and found that the fragments per kilobase of transcript per million mapped reads (FPKM) values of most PI3K- and Akt-related genes were reduced (Fig. 6A). We validated these results by western blot analysis, which revealed that the protein levels of PI3K and Akt in HPV 18+ cells were significantly reduced after 12 h of FFGL exposure (Fig. 6B, 6C). Furthermore, we administered 740 Y-P (an agonist of the PI3K/Akt pathway) in combination with FFGL in HPV 18+ cells and found that the agonist partially attenuated the inhibition of cell viability induced by FFGL (Fig. 6D).
Molecular docking verification of FFGL active compounds and core protein targets
We overlapped the compounds identified by high-resolution mass spectrometry with the top 10 compounds predicted by network pharmacology, which led to the screening of two shared compounds, periplogenin and periplocymarin. Next, Schrödinger molecular docking software was used to dock the two compounds into the core protein Akt1 to conduct the binding free energy analysis. We found that both molecules could access the activity pocket of Akt1. Periplocymarin formed hydrogen bonds with residues CYS-296 and THR-211 of Akt1 at distances of 3.3 A and 1.8 A, respectively (Fig. 7A). Moreover, periplogenin formed a hydrogen bond with residue GLN-79 of Akt1 at a distance of 1.6 A (Fig. 7B). The results of the molecular docking analysis showed that periplocymarin and periplogenin had negative binding free energy to Akt1, indicating that both molecules can spontaneously bind to the Akt1 protein. Further analysis of the results showed that their binding energies were both less than –5 kJ/mol, demonstrating their strong binding affinity (Table 2).
CA is the most common sexually transmitted disease caused by HPV infection, affecting 160–289 people per 100,000 worldwide [49, 50]. Its high rates of transmission and recurrence result in a huge psychosocial and public health burden [1, 51]. Hyperproliferation of keratinocytes is the main feature of CA, a process that is closely associated with HPV genome-regulating events, such as those related to epithelial cell proliferation and differentiation, immunity, and energy metabolism [7, 52, 53]. Current treatments for CA include immunomodulators, such as imiquimod and interferon; cytotoxic drugs, such as 5-fluorouracil; physiotherapy; photodynamic therapy; cryotherapy; and surgery . However, all of these therapies have limitations. Chinese herbal medicines for the treatment of CA and HPV infection have received increasing attention due to their superior clinical efficacy, fewer side effects, and better safety profile, complementing the limitations of current treatment modalities . In previous clinical studies, we found that FFGL had significant efficacy against CA . To further explore the potential mechanism of FFGL, we used network pharmacology, molecular docking, transcriptomics, and in vitro experiments. Figure 8 shows a flow chart of the experiments conducted in this study.
We selected 59 predicted FFGL targets for CA. Further analysis revealed that these potential core targets were concentrated in Akt1 signaling-related pathways. Akt1 belongs to the Akt protein kinase family and plays a role in HPV-mediated hyperproliferation of keratinocytes [45, 55, 56]. It is overexpressed in many cancers and diseases caused by HPV, including CA. A bioinformatics analysis of CA and normal tissues indicated that the PI3K/Akt pathway was significantly enriched in CA tissues . Further studies revealed that the expression levels of PI3K and p-Akt were dramatically higher in CA tissues compared to those in normal tissues [58, 59]. Moreover, clinically effective 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for CA can inhibit the PI3K/Akt pathway, and it has been proven that inhibition of this pathway can decrease the proliferation rate and increase autophagy and apoptosis of HPV 18+ HeLa cells . These studies suggest that Akt1 may be a key target protein for CA treatment.
To further validate this result, we performed a transcriptome analysis of HPV 18+ cells after FFGL intervention. We found that the DEGs were mainly enriched in KEGG pathways such as those related to cytokine-cytokine receptor interaction, PI3K-Akt signaling, and pathways in cancer. In conjunction with our previous network pharmacology findings, we suggest that FFGL may act on HPV 18+ HeLa cells by interfering with the intracellular PI3K/Akt signaling pathway. Next, we determined the expression of PI3k and Akt-related genes in the transcriptome data and found that the FPKM values of most PI3K- and Akt-related genes were reduced. We also performed western blot experiments, which showed that FFGL significantly reduced PI3K and Akt protein levels in HeLa cells and inhibited the PI3K/Akt pathway. Finally, we found that the administration of activators of the PI3K/Akt pathway could partially attenuate the reduction in cell viability induced by FFGL. In summary, we concluded that FFGL can inhibit the viability of HPV 18+ cells through the PI3K/Akt pathway.
The network pharmacology analysis identified 78 FFGL active ingredients from the TCMSP and ETCM databases. Based on the H-C-T network topology analysis and the results of the HPLC–MS experiments, we found that the core compounds contained periplogenin and periplocymarin, which may play an essential role in resistance to HPV infection and in the inhibition of the abnormal activation of the PI3K/Akt pathway in cells. Periplogenin and periplocymarin are cardiac glycosides contained in Periploca sepium Bunge, and they possess potent antitumor activity in addition to their ability to prevent heart failure and their antirheumatic effects [61,62,63,64]. Periplogenin was first isolated from a chloroform extract of Periploca sepium Bunge by Itokawa , and the compound markedly inhibited the growth of the malignant ascites cells of the S180 cell line. Recent studies have shown that periplogenin can target signal transducer and activator of transcription 3 (STAT3) to inhibit the growth of squamous cell carcinoma both in vivo and in vitro . A network pharmacology study  suggested that periplogenin may inhibit nasopharyngeal carcinoma through the PI3K-Akt pathway. Similarly, periplocymarin also exerts antitumor activity  and can inhibit the proliferation of PC3 and U937 cell lines; it can also induce cell arrest in the G2/M phase in U937 cells without causing extensive cell death, making U937 cells sensitive to non-apoptotic doses of apoptosis-inducing ligands . A pharmacokinetic study of periplocymarin showed that it is highly permeable, without p-glycoprotein efflux and cytochrome P450 inhibition, suggesting high bioavailability and low cytotoxicity, with great potential for drug development . Recent studies have found that periplocymarin can induce apoptosis in colorectal cancer cells by inhibiting the PI3K-Akt pathway . Accordingly, our molecular docking results showed that the molecular docking binding energy of both drugs to Akt1 was negative and less than –5, indicating that they could easily bind to the active pocket site of Akt1. These results suggest that FFGL may have reduced HeLa cell viability by inhibiting the PI3K-Akt pathway, an effect mediated by the key components periplogenin and periplocymarin.
In conclusion, FFGL can inhibit the viability of HPV 18+ cells by inhibiting key proteins involved in the PI3K/Akt pathway; this may partially represent the mechanism through which FFGL is efficacious in treating CA. Periplogenin and periplocymarin may play a significant role in this process.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Phosphorylated retinoblastoma tumor suppressor protein
Fu Fang Gang Liu
AKT serine/threonine kinase 1
Phosphatidylinositol 3-kinase/protein kinase B
Traditional Chinese medicine
Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform
Encyclopedia of TCM
Search Tool for the Retrieval of Interacting Genes/Proteins
Liquid chromatography–mass spectrometry
Molecular Complex Detection
Cell Counting Kit-8
National Center for Biotechnology Information
Gene Expression Omnibus
Differentially expressed genes
Structure data file
- RCSB PDB:
Research Collaboratory for Structural Bioinformatics Protein Data Bank
Kyoto Encyclopedia of Genes and Genomes
5-Aminolevulinic acid photodynamic therapy
Signal transducer and activator of transcription 3
Kombe Kombe AJ, Li B, Zahid A, Mengist HM, Bounda GA, Zhou Y, et al. Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation. Front Public Health. 2020;8: 552028.
Cong X, Sun R, Zhang X, Wang Y, Wang L, Yu Y. Correlation of human papillomavirus types with clinical features of patients with condyloma acuminatum in China. Int J Dermatol. 2016;55(7):775–80.
Huang GS, Liu GR, Han YZ, Lin J. The Influence of R-HPV Genotypes on Persistent Patients With Condyloma AcuminatM. Chin J Derm Venereol. 2017;31(10):1100–1+4.
Denny L. Epidemiology and Burden of Disease Associated with HPV Infection. Current Obstetrics and Gynecology Reports. 2016;5(3):189–95.
Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J. 2010;7:11.
Day PM, Schelhaas M. Concepts of papillomavirus entry into host cells. Curr Opin Virol. 2014;4:24–31.
Pal A, Kundu R. Human Papillomavirus E6 and E7: The Cervical Cancer Hallmarks and Targets for Therapy. Front Microbiol. 2019;10:3116.
Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.
Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362–72.
Münger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. Embo J. 1989;8(13):4099–105.
Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.
Vats A, Trejo-Cerro O, Thomas M, Banks L. Human papillomavirus E6 and E7: What remains? Tumour virus research. 2021;11: 200213.
Wu J, Chen C, Zhao KN. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer. Curr Cancer Drug Targets. 2013;13(2):143–56.
Zhang L, Wu J, Ling MT, Zhao L, Zhao K-N. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015;14:87.
Kim SH, Juhnn YS, Kang S, Park SW, Sung MW, Bang YJ, et al. Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ ERK1,2 and PI3K/Akt. Cell Mol Life Sci. 2006;63(7–8):930–8.
Aoki M, Fujishita T. Oncogenic Roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 2017;407:153–89.
Contreras-Paredes A, De la Cruz-Hernández E, Martínez-Ramírez I, Dueñas-González A, Lizano M. E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology. 2009;383(1):78–85.
Menges CW, Baglia LA, Lapoint R, McCance DJ. Human papillomavirus type 16 E7 up-regulates AKT activity through the retinoblastoma protein. Cancer Res. 2006;66(11):5555–9.
Pim D, Massimi P, Dilworth SM, Banks L. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene. 2005;24(53):7830–8.
Henken FE, Banerjee NS, Snijders PJ, Meijer CJ, De-Castro Arce J, Rösl F, et al. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Mol Cancer. 2011;10:71.
Cui BN, Xu X, Zhao YS. Clinical efficacy of compound periploca liquid in treating condyloma acuminatum and its effect on human papilloma virus DNA expression in vitro. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005;25(5):392–6.
Hopkins AL. Network pharmacology. Nat Biotechnol. 2007;25(10):1110–1.
Zhu N, Hou J. Molecular mechanism of the anti-inflammatory effects of Sophorae Flavescentis Aiton identified by network pharmacology. Sci Rep. 2021;11(1):1005.
Zhang X, Gao R, Zhou Z, Sun J, Tang X, Li J, et al. Uncovering the mechanism of Huanglian-Wuzhuyu herb pair in treating nonalcoholic steatohepatitis based on network pharmacology and experimental validation. J Ethnopharmacol. 2022;296: 115405.
Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of cheminformatics. 2014;6:13.
Xu HY, Zhang YQ, Liu ZM, Chen T, Lv CY, Tang SH, et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47(D1):D976–82.
Wang T, Jiang X, Ruan Y, Li L, Chu L. The mechanism of action of the combination of Astragalus membranaceus and Ligusticum chuanxiong in the treatment of ischemic stroke based on network pharmacology and molecular docking. Medicine. 2022;101(28): e29593.
Wang T, Zhou Y, Wang K, Jiang X, Wang J, Chen J. Prediction and validation of potential molecular targets for the combination of Astragalus membranaceus and Angelica sinensis in the treatment of atherosclerosis based on network pharmacology. Medicine. 2022;101(26):e29762.
Wang X, Shen Y, Wang S, Li S, Zhang W, Liu X, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 2017;45(W1):W356–60.
Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357–64.
UniProt. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 2021;49(D1):D480-d9.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
Safran M, Rosen N, Twik M, BarShir R, Stein TI, Dahary D, et al. The GeneCards Suite. In: Abugessaisa I, Kasukawa T, editors., et al., Practical Guide to Life Science Databases. Singapore: Springer Nature Singapore; 2021. p. 27–56.
Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–55.
Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.
Wang T, Jiang X, Ruan Y, Zhuang J, Yin Y. Based on network pharmacology and in vitro experiments to prove the effective inhibition of myocardial fibrosis by Buyang Huanwu decoction. Bioengineered. 2022;13(5):13767–83.
Li J, Miao B, Wang S, Dong W, Xu H, Si C, et al. Hiplot: a comprehensive and easy-to-use web service boosting publication-ready biomedical data visualization. 2022:2022.03.16.484681.
Bu D, Luo H, Huo P, Wang Z, Zhang S, He Z, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. Nucleic Acids Res. 2021;49(W1):W317–25.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Cambridge (Mass)). 2021;2(3):100141.
Kanehisa M. Toward understanding the origin and evolution of cellular organisms. Protein science : a publication of the Protein Society. 2019;28(11):1947–51.
Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51(D1):D587–92.
Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2021;49(D1):D1388–95.
Burley SK, Bhikadiya C, Bi C, Bittrich S, Chen L, Crichlow GV, et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res. 2020;49(D1):D437–51.
Coffer PJ, Woodgett JR. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991;201(2):475–81.
Carrillo-Beltrán D, Muñoz JP, Guerrero-Vásquez N, Blanco R, León O, de Souza Lino V, et al. Human Papillomavirus 16 E7 Promotes EGFR/PI3K/AKT1/NRF2 Signaling Pathway Contributing to PIR/NF-κB Activation in Oral Cancer Cells. Cancers (Basel). 2020;12(7):1904.
Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA. Ligand-Independent EGFR Signaling. Cancer Res. 2015;75(17):3436–41.
Abraham AG, O’Neill E. PI3K/Akt-mediated regulation of p53 in cancer. Biochem Soc Trans. 2014;42(4):798–803.
Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013;13:39.
Gilson R, Nugent D, Werner RN, Ballesteros J, Ross J. 2019 IUSTI-Europe guideline for the management of anogenital warts. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020;34(8):1644–53.
Sindhuja T, Bhari N, Gupta S. Asian guidelines for condyloma acuminatum. J Infect Chemother. 2022.
Doorbar J. The papillomavirus life cycle. J Clin Virol. 2005;32(Suppl 1):S7-15.
Della Fera AN, Warburton A, Coursey TL, Khurana S, McBride AA. Persistent Human Papillomavirus Infection. Viruses. 2021;13(2):321.
Lin J, Chen L, Qiu X, Zhang N, Guo Q, Wang Y, et al. Traditional Chinese medicine for human papillomavirus (HPV) infections: A systematic review. Biosci Trends. 2017;11(3):267–73.
Paolini F, Carbone A, Benevolo M, Silipo V, Rollo F, Covello R, et al. Human Papillomaviruses, p16INK4a and Akt expression in basal cell carcinoma. J Experiment Clin Cancer Res. 2011;30(1):108.
Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A. 1987;84(14):5034–7.
Zhong Y, Wei J, Song W, Wang Q, Zhang Z, Liu H, et al. Identification of novel biomarkers and key pathways of condyloma acuminata. Genomics. 2022;114(2):110303.
Man X, Zhang X, Tang J, Zheng Z, Yang D, Chen Y, et al. Expressions of phosphatidylinositol 3 kinase and phosphorylated Akt in condyloma acuminatum and cervical squamous cell carcinoma. Chinese Journa of Dermatology. 2011;44(12):857–60.
Chen M, Wang J, Fang R, Jia S, Mo Y, Mo J. Expression of Caspase 8 and phospho-Akt in condyloma acuminatum lesions. Chinese Journa of Dermatology. 2017;50(5):366–9.
Xie J, Wang S, Li Z, Ao C, Wang J, Wang L, et al. 5-aminolevulinic acid photodynamic therapy reduces HPV viral load via autophagy and apoptosis by modulating Ras/Raf/MEK/ERK and PI3K/AKT pathways in HeLa cells. J Photochem Photobiol, B. 2019;194:46–55.
Newman RA, Yang P, Pawlus AD, Block KI. Cardiac glycosides as novel cancer therapeutic agents. Mol Interventions. 2008;8(1):36–49.
Kumavath R, Paul S, Pavithran H, Paul MK, Ghosh P, Barh D, et al. Emergence of Cardiac Glycosides as Potential Drugs: Current and Future Scope for Cancer Therapeutics. Biomolecules. 2021;11(9):1275.
Zhang HY, Xu WQ, Wang YW, Omari-Siaw E, Wang Y, Zheng YY, et al. Tumor targeted delivery of octreotide-periplogenin conjugate: Synthesis, in vitro and in vivo evaluation. Int J Pharm. 2016;502(1–2):98–106.
Zhang H, Xu W, Omari-Siaw E, Liu Y, Chen B, Chen D, et al. Redox-responsive PEGylated self-assembled prodrug-nanoparticles formed by single disulfide bond bridge periplocymarin-vitamin E conjugate for liver cancer chemotherapy. Drug Delivery. 2017;24(1):1170–8.
Itokawa H, Xu JP, Takeya K. Studies on chemical constituents of antitumor fraction from Periploca sepium BGE. I Chemical & pharmaceutical bulletin. 1987;35(11):4524–9.
Hu Y, Liu F, Jia X, Wang P, Gu T, Liu H, et al. Periplogenin suppresses the growth of esophageal squamous cell carcinoma in vitro and in vivo by targeting STAT3. Oncogene. 2021;40(23):3942–58.
Ye H, Wei X, Meng C, Wei Y, Liang G, Huang Z, et al. Mechanism of Action of Periplogenin on Nasopharyngeal Carcinoma Based on Network Pharmacology and Experimental Study of Vitamin E Coupled with Periplogenin Self-Assembled Nano-Prodrug for Nasopharyngeal Carcinoma. J Biomed Nanotechnol. 2020;16(9):1406–15.
Zhang HY, Xu WQ, Zheng YY, Omari-Siaw E, Zhu Y, Cao X, et al. Octreotide-periplocymarin conjugate prodrug for improving targetability and anti-tumor efficiency: synthesis, in vitro and in vivo evaluation. Oncotarget. 2016;7(52):86326–38.
Bloise E, Braca A, De Tommasi N, Belisario MA. Pro-apoptotic and cytostatic activity of naturally occurring cardenolides. Cancer Chemother Pharmacol. 2009;64(4):793–802.
Martey ON, He X, Xing H, Deng F, Feng S, Li C, et al. Periplocymarin is a potential natural compound for drug development: highly permeable with absence of P-glycoprotein efflux and cytochrome P450 inhibitions. Biopharm Drug Dispos. 2014;35(4):195–206.
Cheng Y, Wang G, Zhao L, Dai S, Han J, Hu X, et al. Periplocymarin Induced Colorectal Cancer Cells Apoptosis Via Impairing PI3K/AKT Pathway. Front Oncol. 2021;11:753598.
We would like to thank Editage (www.editage.cn) for English language editing.
This study was funded by the National Natural Science Foundation of China (No. 81173274) and the Science and Technology Innovation Project of the China Academy of Chinese Medical Science (No.CI2021A02305).
Ethics approval and consent to participate
Consent for publication
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1.
Additional file 2.
Additional file 3.
Additional file 4.
Additional file 5.
Additional file 6.
Additional file 7.
Additional file 8.
Additional file 9.
Additional file 10.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Fan, Z., Wang, S., Xu, C. et al. Mechanisms of action of Fu Fang Gang Liu liquid in treating condyloma acuminatum by network pharmacology and experimental validation. BMC Complement Med Ther 23, 128 (2023). https://doi.org/10.1186/s12906-023-03960-7
- Condyloma acuminatum
- Fu Fang Gang Liu liquid
- Network pharmacology
- Molecular docking